Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19

[admin]

Trial meets endpoints in safety and efficacyIND Letter from the CDSCO to optimize dosageEstablishment of an Indian Subsidiary to commercialize ProLectin-M BOSTON, MASSACHUSETTS, Dec. 28, 2022 (GLOBE NEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT) (the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral causing diseases announces that Crystal Research provided an update on BIXT. Crystal research reported that the Company announced